Sanofi sales reps call in for layoff news

It's tough to be a pharma rep these days, especially if you work for one of the companies that's in the midst of laying off your colleagues (or, potentially, you). And unfortunately that list seems to be growing by the day: Roche last month, Novartis ($NVS) this week, and if Pharmalot's sources are correct, at least one more drugmaker to come by year's end.

But as BNet Pharma reports, Sanofi-Aventis ($SNY) reps win the prize for pain this week. Previously announced cuts of 1,700 positions went through yesterday, and, perhaps as part of its overall push for efficiency, the company didn't take the time to notify laid-off salespeople individually. Instead, Sanofi managers took the cattle-call approach: Each sales rep was scheduled for one of two group teleconferences, with one of those calls devoted to those who got to keep their jobs and the other to those shown the door.

Some consolation for those suffering Sanofi-ites, however. Some 250 contract sales reps would share the layoff pain. And management officially says that the latest sales layoffs will put the marketing force at the right size through 2013. So, no nail-biting over potential job loss for at least three years.

- get the BNet piece
- see a related interview at Pharmalot

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.